All-in-One Vector Approach
Celyad Oncology focuses on using a single vector approach to generate CAR T cells
Encoding multiple components of the CAR T construct, including the chimeric antigen receptor T cell (CAR T), selection marker (i.e. truncated CD19), therapeutic add-ons (i.e. cytokines), non-gene edited allogeneic technology (i.e. TIM) and short hairpin RNAs (shRNA) in a single vector helps Celyad Oncology to simplify the design and development of our cell therapy candidates.
Our next-generation of therapies stem from shRNA CAR T technology platform. This platform uses the first non-gene-edited, all-in-one vector approach to develop off-the-shelf CAR Ts.
This single transduction, plug and play approach to CAR T development also helps to streamline process development and manufacturing while broadening the potential applicability of our candidates.
When coupled with our allogeneic platforms, including both our TIM and shRNA technologies, the All-in-One Vector approach avoids multiple genetic modifications and costs associated with additional Good Manufacturing Practice (GMP) grade vectors. In addition, when combined with our shRNA technology, the single vector approach demonstrates efficient expression of multiple shRNAs and enables the generation of a homogenous CAR T cell population through a single step enrichment.